ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.44
0.30%
US Tech 100
18,289.20
-1.44%
S&P 500
5,427.79
-0.65%
US Dollar vs CAD
1.38475
-0.06%
Bitcoin
65,727.56
-1.64%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) News

AIM

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:AIM
DateTimeSourceHeadlineSymbolCompany
07/30/20246:14AMEdgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]AMEX:AIMAIM ImmunoTech Inc
07/29/20248:15AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
07/25/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:AIMAIM ImmunoTech Inc
07/25/20244:00PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:AIMAIM ImmunoTech Inc
07/24/20247:50AMGlobeNewswire Inc.AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination TherapyAMEX:AIMAIM ImmunoTech Inc
07/15/20244:19PMEdgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]AMEX:AIMAIM ImmunoTech Inc
07/15/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
07/11/20244:16PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933AMEX:AIMAIM ImmunoTech Inc
07/03/20247:55AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
06/10/20247:55AMGlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Pitch ConferenceAMEX:AIMAIM ImmunoTech Inc
06/03/20249:15AMEdgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
06/03/20249:05AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:AIMAIM ImmunoTech Inc
06/03/20248:15AMGlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Lunch Break SeriesAMEX:AIMAIM ImmunoTech Inc
05/31/20247:30AMGlobeNewswire Inc.AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct OfferingAMEX:AIMAIM ImmunoTech Inc
05/31/20247:14AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:AIMAIM ImmunoTech Inc
05/20/20248:15AMGlobeNewswire Inc.AIM ImmunoTech to Participate in Two Upcoming Investor ConferencesAMEX:AIMAIM ImmunoTech Inc
05/16/20246:30AMGlobeNewswire Inc.AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
05/15/20243:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:AIMAIM ImmunoTech Inc
05/09/20247:50AMGlobeNewswire Inc.AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
05/07/20247:30AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
05/07/20247:30AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
05/06/20247:30AMGlobeNewswire Inc.AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®AMEX:AIMAIM ImmunoTech Inc
04/29/20247:55AMGlobeNewswire Inc.AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
04/25/20247:45AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
04/18/20247:45AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
04/15/20247:55AMGlobeNewswire Inc.AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsAMEX:AIMAIM ImmunoTech Inc
04/11/202410:00AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
04/10/20247:21AMGlobeNewswire Inc.AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerAMEX:AIMAIM ImmunoTech Inc
04/02/20246:30AMGlobeNewswire Inc.AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
03/28/20247:05AMGlobeNewswire Inc.AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceAMEX:AIMAIM ImmunoTech Inc
 Showing the most relevant articles for your search:AMEX:AIM

Your Recent History

USOTC
MONI
Moon Equity (PK)
USOTC
MWWC
Marketing Worldwide (PK)
USOTC
CLNV
Clean Vision (QB)
NASDAQ
NVDA
NVIDIA
USOTC
AHRO
Authentic (CE)
USOTC
GDVM
Global Developments (PK)
USOTC
SAPX
Seven Arts Entertainment (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
CNNA
Cann American (CE)
USOTC
BIEL
Bioelectronics (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
NWPN
Now (PK)
COIN
XRPUSD
Ripple
USOTC
RDGL
Vivos (QB)
USOTC
ERHE
ERHC Energy (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved